Plasma TREM2 - A Novel Non-Invasive NASH Biomarker
A plasma protein that can identify NASH patients from a single blood sample with high confidence
Published: 6th October 2021
Patents
- Patent application covering use of sTREM2 as clinical biomarker of NASH filed in May 2021
- Additional matter of substance patent planned based on sequence of antibody developed for in house assay
- The already filed patent dominates the use of sTREM2 as NASH biomarker, preventing others from developing own assay for clinical use
IP Status
- Patent application submitted
Seeking
- Development partner